LitCovid-sentences  

PMC:7534795 / 30490-32766 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T211 0-148 Sentence denotes Table 4 Overview of the pharmacological interventions under investigation targeting hypercoagulability and platelet activation in COVID-19 patients.
T212 149-255 Sentence denotes Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference
T213 256-349 Sentence denotes • Heparin anticoagulant treatment in sepsis-induced coagulopathy • Retrospective cohort study
T214 350-369 Sentence denotes • ≥ 18 years of age
T215 370-397 Sentence denotes • Severe COVID-19 infection
T216 398-463 Sentence denotes • Evaluation of 28-day mortality in heparin and non-heparin users
T217 464-514 Sentence denotes • 48.5% comorbid hypertension and/or heart disease
T218 515-532 Sentence denotes • N = 99 heparin
T219 533-758 Sentence denotes • N = 350 no heparin • Unfractionated (10, 000–15, 000 U/day) or low molecular weight heparin (40–60 mg enoxaparin/day) for 7 days or longer • No difference in 28-day mortality endpoint between heparin and non-heparin users.
T220 759-869 Sentence denotes • Lower 28-day mortality in patients with sepsis-induced coagulopathy (SIC) score of ≥4 in stratified analysis
T221 870-1085 Sentence denotes • Odd Ratio (OR) 0.372 (95% CI 0.154–0.901) • Heparin may be associated with a lower 28-day mortality rate only in patients with enhanced coagulopathy risk such as SIC score of 4 or greater (Tang, Bai, et al., 2020)
T222 1086-1240 Sentence denotes • Antiplatelet and anticoagulant combination therapy for hypoxemia, respiratory failure, and cardiac adverse events • Case control, proof-of-concept study
T223 1241-1292 Sentence denotes • Adult patients with hypoxemic respiratory failure
T224 1293-1361 Sentence denotes • N = 5 ASA + clopidogrel + tirofiban + fondaparinux + standard care
T225 1362-1422 Sentence denotes • N = 5 matched controls given low molecular weight heparin
T226 1423-1493 Sentence denotes • Secondary outcome included major and minor cardiac adverse events 1.
T227 1494-1600 Sentence denotes Single dose of acetylsalicylic acid (ASA) 250 mg i.v. and single loading dose of oral clopidogrel 300 mg2.
T228 1601-1660 Sentence denotes ASA and clopidogrel continued at 75 mg orally for 30 days3.
T229 1661-1760 Sentence denotes Tirofiban 25 μg/kg as bolus i.v. injection, then 0.15 μg/kg/min continuous i.v. infusion for 48 h4.
T230 1761-1890 Sentence denotes Fondaparinux 2.5 mg/day s.c. for the duration of the hospital stay • Significant improvement in alveolar-arterial oxygen gradient
T231 1891-1944 Sentence denotes • Significant improvement in CRP and lymphocyte count
T232 1945-2078 Sentence denotes • Patients in treatment group did not experience any cardiac adverse events • Small study and not a randomized controlled trial (RCT)
T233 2079-2276 Sentence denotes • Intensive antithrombotic therapy may be useful in patients with severe respiratory distress with prothrombotic state at risk for acute cardiac events (Viecca, Radovanovic, Forleo, & Santus, 2020)